FDA Panel: Approve Rivaroxaban for Stroke Prevention - Internal Medicine News Digital Network PDF Print
Internal Medicine News Digital Network
The Food and Drug Administration's Cardiovascular and Renal Drugs Advisory Committee advisory panel on Sept. 8 voted 9-2, with 1 abstention, that the anticoagulant rivaroxaban is effective for prevention of stroke in nonvalvular atrial fibrillation. ...
Bayer Confident in Results of ROCKET AF Study to Be Reviewed by the FDA

...

 
Share |
Copyright © 2025 Global Dialysis. All Rights Reserved.